Gao yijin

Dr. Gao yijin

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
GYGao yijin
Gao yijin
MSMeng Su
Meng Su
JTJing-Yan Tang
Jing-Yan Tang
CPCi Pan
Ci Pan
JCJing Chen
Jing Chen
We reported the outcome of 150 children newly diagnosed with multisystem langerhans cell histiocytosis following a langerhans cell histiocytosis-II-based protocol (arm B). However, the continuation treatment was extended to 56 weeks and etoposide was omitted from the continuation treatment. Risk organ (RO) involvement was defined as: liver (≥3 cm with or without functional impairment); spleen (≥2 cm below the costal margin in the midclavicular line); hematopoietic system (hemoglobin <100 g/L, and/or white blood cell count <4.0×109/L, and/or platelets <100×109/L). The lungs are not considered a RO in the current study. For the 59 patients with RO involvement (RO+), the rapid response rate (week 6) was 61.0% and the 3-year overall survival 73.4%±5.9%. Rapid responders had a better 3-year survival rate than poor responders (90.9%±5.0% vs. 45.7%±11.0%, P<0.001). Ninety-one patients without RO involvement (RO−) had a relatively low 3-year cumulative reactivation rate (10.7%). No deaths occurred in this subgroup and the 3-year overall survival of RO− patients was 100%. Poor responders of RO+ patients had an extremely poor prognosis. An effective salvage therapy is essential for this high-risk group. The initial treatment intensity and duration of continuation therapy both impact disease reactivation in RO− patients.

11 July 2022 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
YYYi Yang
Yi Yang
JZJie Zhao
Jie Zhao
YZYingwen Zhang
Yingwen Zhang
TFTianyue Feng
Tianyue Feng
BYBo Yv
Bo Yv
LYLi yanxin
Li yanxin
Objective: MYCN oncogene amplification is associated with treatment failure and poor prognosis in neuroblastoma. To date, most detection methods of MYCN focus on DNA copy numbers instead of protein expression, which is the real one performing biological function, for poor antibodies. The current investigation was to explore a fast and reliable way to detect MYCN protein expression and evaluate its performance in predicting prognosis. Methods: Several MYCN antibodies were used to detect MYCN protein expression by immunohistochemistry (IHC), and one was chosen for further study. We correlated the IHC results of MYCN from 53 patients with MYCN fluorescence in situ hybridization (FISH) and identified the sensitivity and specificity of IHC. The relationship between patient prognosis and MYCN protein expression was detected from this foundation. Results: MYCN amplification status detected by FISH was most valuable for INSS stage 3 patients. In the cohort of 53 samples, IHC test demonstrated 80.0–85.7% concordance with FISH results. Further analyzing those cases with inconsistent results, we found that patients with MYCN amplification but low protein expression tumors always had a favorable prognosis. In contrast, if patients with MYCN non-amplified tumors were positive for MYCN protein, they had a poor prognosis. Conclusion: MYCN protein level is better than MYCN amplification status in predicting the prognosis of neuroblastoma patients. Joint of FISH and IHC could confirm MYCN protein stability and achieve better prediction effect than the singular method.

11 May 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
TLTing Li
Ting Li
LSLili Song
Lili Song
YZYingwen Zhang
Yingwen Zhang
YHYali Han
Yali Han
ZZZhiyan Zhan
Zhiyan Zhan
GYGao yijin
Gao yijin
Patients with relapsed/refractory Burkitt's lymphoma (BL) have a dismal prognosis. Current research efforts aim to increase cure rates by identifying high‐risk patients in need of more intensive or novel therapy. The 8q24 chromosomal translocation of the c‐Myc gene, a main molecular marker of BL, is related to the metabolism by regulating phosphoribosyl pyrophosphate synthetase 2 (PRPS2). In our study, BL showed significant resistance to thiopurines. PRPS2 homologous isoenzyme, PRPS1, was demonstrated to play the main role in thiopurine resistance. c‐Myc did not have direct effects on thiopurine resistance in BL for only driving PRPS2. PRPS1 wild type (WT) showed different resistance to 6‐mercaptopurine (6‐mp) in different metabolic cells because it could be inhibited by adenosine diphosphate or guanosine diphosphate negative feedback. PRPS1 A190T mutant could dramatically increase thiopurine resistance in BL. The interim analysis of the Treatment Regimen for Children or Adolescent with mature B cell non‐Hodgkin's lymphoma in China (CCCG‐B‐NHL‐2015 study) confirms the value of high‐dose methotrexate (MTX) and cytarabine (ARA‐C) in high‐risk paediatric patients with BL. However, there remains a subgroup of patients with lactate dehydrogenase higher than four times of the normal value (4N) for whom novel treatments are needed. Notably, we found that the combination of thiopurines and the phosphoribosylglycinamide formyltransferase (GART) inhibitor lometrexol could serve as a therapeutic strategy to overcome thiopurine resistance in BL.

14 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SJShayi Jiang
Shayi Jiang
KDKuiran Dong
Kuiran Dong
KLKai Li
Kai Li
JLJiangbin Liu
Jiangbin Liu
XDXin Du
Xin Du
GYGao yijin
Gao yijin
Objective: The aim was to describe the clinical features of extracranial germ cell tumors (GCTs) in pediatrics and study the clinical risk factors related to survival for malignant germ cell tumors (MGCTs) in order to optimize therapeutic options. Methods: The clinical data of children with extracranial GCTs in three children’s medical centers in Shanghai were retrospectively analyzed. Results: In total, 1007 cases of extracranial GCTs diagnosed between 2010 and 2019 were included in this study, including teratomas (TERs) 706 (70.11%) and MGCTs 301 (29.89%). There were twice as many TER cases as MGCT cases. Approximately 50% of children with GCTs were <3 years old (43.39% for TERs, 67.13% for MGCTs). GCTs in children of different ages show differences in tumor anatomical locations and pathological subtypes. The 5-year event-free survival (EFS) and overall survival (OS) of all patients with MGCTs were 82.33% (95% CI, 77.32%, 86.62%) and 94.13% (95% CI, 90.02%, 96.69%), respectively. The multivariate Cox regression analysis identified a primary site in the mediastinum and alpha fetoprotein (AFP) levels ≥10,000 ng/mL as independent adverse prognostic factors (p < 0.0.0001, χ2 = 23.6638, p = 0.0225, χ2 = 5.2072.). There were no significant differences in OS among children receiving various chemotherapy regimens, such as the BEP, PEB, JEB and other regimens (VBP/VIP and AVCP/IEV) (p < 0.05). Conclusions: The clinical features of GCTs in Chinese pediatrics are similar to those reported in children in Europe and America. The age distribution of pathological types and primary sites in GCTs reflect the developmental origin of type I and type II GCTs transformed from mismigration primordial germ cells (PGCs). Optimizing the current platinum-based chemotherapy regimens and exploring the treatment strategies for MGCTs of the mediastinum are future research directions.

22 February 2023 in International Journal of Cancer
Verified
Journal Article
Closed access
HXHui Xiao
Hui Xiao
SWSiqi Wang
Siqi Wang
YTYuejia Tang
Yuejia Tang
SLShanshan Li
Shanshan Li
YJYufeng Jiang
Yufeng Jiang
GYGao yijin
Gao yijin

5 January 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
DMDaniel C. Moreira
Daniel C. Moreira
SHSaman K. Hashmi
Saman K. Hashmi
AAAllyson Andujar
Allyson Andujar
FBFair Berg
Fair Berg
KCKristy Conger
Kristy Conger
CRCarlos Rodríguez‐Galindo
Carlos Rodríguez‐Galindo
There is currently a global shortage of healthcare professionals equipped to handle the rising burden of childhood cancer. St. Jude Global is an initiative to improve survival rates of children with cancer worldwide while improving access to quality care. One of the overriding goals of St. Jude Global is focused on education: the training of the clinical workforce needed to expand quality care for all children with cancer. Herein, we describe the St. Jude Global Academy (SJGA) and its programs. The three main workstreams of the SJGA are: clinical training programs, courses, and distance learning. St. Jude collaborates with eight institutions in seven low‐ and middle‐income countries to train pediatric subspecialists. Each year, approximately 20 new fellows start at these clinical training programs. To date, 92 specialists have been trained. The SJGA's courses create educational opportunities that provide a structured learning experience in key areas that are relevant to pediatric cancer care. To date, 1081 participants from 372 institutions in 84 countries have successfully completed these educational opportunities. Cure4Kids is the SJGA's distance learning platform. Over 9000 healthcare professionals in 177 countries use Cure4Kids. The platform receives 1400 visits and over 13,000 page views per day. The SJGA's multifaceted approach encompasses various disciplines and skills, providing healthcare professionals from around the world the skills to address the needs of children diagnosed with cancer in their respected institutions. These efforts are essential for building workforce capacity to improve outcomes.